RATIONALE
Minimally Invasive Thyroid Treatments (MITT) are reaching an increasingly important role in the management of patients with benign and malignant thyroid diseases.
The MITT group has been founded in 2018 to promote multidisciplinary partnership among physicians with different expertise who share the interest in MITT and to improve the clinical, diagnostic, and therapeutic management of benign and malignant thyroid and parathyroid glands diseases.
For the proper application of MITT, a deep knowledge of thyroid US technique and exam execution an interpretation are of paramount importance. For this reason, before the 2025 MITT meeting a full morning will be dedicated to a thyroid US ultrasound, where all the crucial aspects related to MITT will be presented and discussed.
Than, during the 2025 MITT meeting, the present guidelines on both benign and malignant thyroid disease management will be presented, together with the most widely used technologies used for ablation. Also, the most updated evidence on the application of MITT in benign and malignant thyroid conditions will be presented and discussed.
Furthermore, a series of real-life clinical cases will be presented and discussed between the expert panel and the participants.
During the whole meeting and at the end of the second day hands-on workshops will be available for those who will want to try the different available technologies and techniques on dedicated phantoms.
The MITT group has been founded in 2018 to promote multidisciplinary partnership among physicians with different expertise who share the interest in MITT and to improve the clinical, diagnostic, and therapeutic management of benign and malignant thyroid and parathyroid glands diseases.
For the proper application of MITT, a deep knowledge of thyroid US technique and exam execution an interpretation are of paramount importance. For this reason, before the 2025 MITT meeting a full morning will be dedicated to a thyroid US ultrasound, where all the crucial aspects related to MITT will be presented and discussed.
Than, during the 2025 MITT meeting, the present guidelines on both benign and malignant thyroid disease management will be presented, together with the most widely used technologies used for ablation. Also, the most updated evidence on the application of MITT in benign and malignant thyroid conditions will be presented and discussed.
Furthermore, a series of real-life clinical cases will be presented and discussed between the expert panel and the participants.
During the whole meeting and at the end of the second day hands-on workshops will be available for those who will want to try the different available technologies and techniques on dedicated phantoms.